Eisai Clinical Trials

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer’s Disease Followed by a 12 Week Open-Label Extension Period

E2020-A001-315

Study Overview

E2020
donepezil
NCT00096473
Jan 2001 - Jun 2005
Alzheimer's disease
Assessments of global and cognitive function of Severe AD patients

  • Males and females (age 50 years and over)

  • Completed

  • Phase 3

  • Australia, Canada, France, Ireland, United Kingdom, United States See more

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer’s disease. Neurology 2007;69:459-69.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR